NEW YORK (GenomeWeb News) – Shares of Genomic Health, Thermo Fisher Scientific, and Invitrogen rose significantly today after all three firms posted strong fourth-quarter results.
Genomic Health led the charge, with its shares rising 16 percent to $23.04 in mid-afternoon trade on the Nasdaq. After the close of the market yesterday, the firm said that its revenues for the quarter ended Dec. 31, 2007, grew by 124 percent to $19.3 million from $8.6 million in the fourth quarter of 2006, while cutting its net loss by a third.
Thermo Fisher Scientific’s shares were up 7.5 percent at $54 on the New York Stock Exchange after the firm reported this morning that its fourth-quarter revenues rose 12 percent on a pro forma basis to $2.62 billion.
Thermo Fisher also posted a fourth-quarter profit of $239.8 million, or $.54 per share. The reported revenues and profit beat analysts’ expectations.
Invitrogen gained 6.2 percent to $88.58 in afternoon trade on the Nasdaq after it reported 12 percent revenue growth to $336.4 million for the fourth quarter. The firm also posted net income of $41.1 million, or $.83 per share, compared to a net loss of $100.2 million, or $2.03 million per share.